Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

GC-1118A

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

GC Biopharma

Drug class:

EGFR inhibitor

Related drugs:

‹

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

›

EGFR overexpression	Gastric Cancer	EGFR overexpression	Gastric Cancer	GC-1118A Sensitive: C3 – Early Trials GC-1118A Sensitive : C3	GC-1118A Sensitive: C3 – Early Trials GC-1118A Sensitive : C3
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	GC-1118A Sensitive: D – Preclinical GC-1118A Sensitive : D	GC-1118A Sensitive: D – Preclinical GC-1118A Sensitive : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	RTB101 + GC-1118A Sensitive: D – Preclinical RTB101 + GC-1118A Sensitive : D	RTB101 + GC-1118A Sensitive: D – Preclinical RTB101 + GC-1118A Sensitive : D